New capability delivers enhanced performance for high-throughput single cell experiments
SEATTLE--BUSINESS WIRE--
Parse Biosciences, a leader in accessible and scalable single cell sequencing solutions, today announced a significant expansion of its Evercode™ WT Mega Kit functionality. Researchers can now analyze up to 384 samples and 1 million cells in a single run, unlocking new possibilities for high-throughput studies.
While single cell technologies have steadily advanced, many still face limitations in handling large numbers of cells and samples simultaneously. However, these capabilities are precisely what researchers need for high-throughput drug screening, genetic screening, and time-course experiments that demand both scalability and precision. With the expanded functionality of the Evercode WT Mega Kit, scientists can screen 1 million cells across 384 samples in a single experiment, streamlining workflows and enabling new discoveries.
The new functionality is further enhanced when paired with Evercode™ Low Input Fixation, providing an additional advantage for researchers working with limited cell numbers per sample. This combination is especially beneficial for rare or precious sample types, enabling robust testing of multiple conditions and replicates even with lower sample inputs.
“We are excited to provide this functionality to the research community,” said Charlie Roco, Co-founder and CTO of Parse Biosciences. “By enabling the simultaneous analysis of so many samples and cells, we’re providing scientists with the tools they need to explore new possibilities and accelerate progress in areas like drug discovery, functional genomics, and beyond.”
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is now used by over 2,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107225465/en/
Contact details:
Parse Media Contact:
Shev Rush, SRPR
[email protected] | 213.503.4828